Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

SPECIALITY MEDICINES LIMITED

Healthcare › Pharmaceuticals & Biotechnology
₹141.10
at close · 27 Oct 2026
▲ 0.10 (+0.07%)
ThemesArtificial Intelligence· mention

Latest filings

  1. Compliance certificate under SEBI Regulation 74(5) for Sep 2026 quarter · Compliance
  2. Insider trading window closed ahead of H2 FY26 results · Compliance
  3. 5th AGM results: both resolutions passed with 100% approval · Board & Shareholder Meetings
All filings ↓
Ask Nexa about SPECIALITY MEDICINES LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Markets and distributes finished pharmaceutical formulations in India as its single reportable segment, with FY2026 revenue from operations of Rs 7,528.51 lakh, up 29.2% from Rs 5,827.14 lakh in FY2025, and net profit of Rs 1,303.29 lakh. The company recently listed on BSE on March 30, 2026 under scrip code 544738 following an IPO completed in March 2026. Total equity capital stands at Rs 8.78 crore across 87,85,796 shares of Rs 10 each. Disclosed operating costs comprise employee cost at 2.3% of revenue and other operating expenses at 7.6% of revenue, with capex of Rs 0.008 crore in FY26. The company holds startup recognition under Section 80-IAC of the Income Tax Act, providing tax benefits.

Operating scale
BSE listing
Scrip code 544738, listed March 30, 2026FY26
Reportable segments
1 (pharma marketing and distribution)FY26
IPO
23,50,000 equity shares at Rs 124, raised Rs 2,914 lakhMarch 2026
Total equity shares
87,85,796 shares of Rs 10 each (Rs 8.78 crore capital)FY26
Employee cost share
2.3% of revenueFY26
Capex
Rs 0.008 croreFY26
Who pays it
Indian pharmaceutical buyers of finished formulations
Kind of business
Asset-light pharmaceutical marketing and distribution
Where it sits
BSE-listed single-segment pharma marketing and distribution company, recently listed via March 2026 IPO
Market Cap
₹124 Cr
P / E (TTM)
—
EV / EBITDA
—
Div Yield
—
Growth
—·
Revenue 5y CAGR
PAT — · EBITDA —
Quality
18.8%▲
ROCE (FY26)
ROE — · margin —
Leverage
—·
Debt / Equity · borrowings not filed
Moves on a normal day
3.08%·
Median daily move
Last 134 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#26/158
ROCE#48/183

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Returns on capital 18.8%
#48 of 183 in Pharmaceuticals on the latest reported figures
Concerns
Nothing flagged in the filed numbers.

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SPECIALITY MEDICINES LIMITED's filed financials and exchange disclosures

What does SPECIALITY MEDICINES LIMITED do?

SPECIALITY MEDICINES LIMITED is a Pharmaceuticals & Biotechnology company listed on BSE.

How much does the SPECIALITY MEDICINES LIMITED share price move in a day?

On a typical session SPECIALITY MEDICINES LIMITED moves 3.08% — that is the median absolute close-to-close move across its last 134 trading days. MarketPing measures each filing's price reaction against it.

Where can I track SPECIALITY MEDICINES LIMITED's announcements?

Every NSE and BSE filing by SPECIALITY MEDICINES LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.